Invasive Melanoma Arising in a BAP1-Inactivated Melanocytic Tumor With NRAS Mutation: A Report of Exceptional Case With Emphasis on Its Genomic Features and Review of the Literature
Muath Alyahya, Nyi Nyi May-Phyo, Ami Wang, Shamini Selvarajah, Cuihong Wei, Calvin Tseng, Tao Wang, Tara Baetz, Zaid Saeed Kamil
{"title":"Invasive Melanoma Arising in a BAP1-Inactivated Melanocytic Tumor With NRAS Mutation: A Report of Exceptional Case With Emphasis on Its Genomic Features and Review of the Literature","authors":"Muath Alyahya, Nyi Nyi May-Phyo, Ami Wang, Shamini Selvarajah, Cuihong Wei, Calvin Tseng, Tao Wang, Tara Baetz, Zaid Saeed Kamil","doi":"10.1111/cup.14839","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>BAP1-inactivated melanocytic tumor is a distinct entity with loss of BAP1 protein and epithelioid morphology. It shares histopathologic features with Spitz nevus and nevoid melanoma, and it can occur sporadically or with germline BAP1 predisposition syndrome. These lesions typically have tumor-infiltrating lymphocytes and infrequent mitoses. They are generally indolent, though melanoma can arise in both germline and sporadic cases. Most show <i>BRAF</i> V600E and <i>BAP1</i> mutations. We describe four tumors in one patient diagnosed with BAP1-tumor predisposition syndrome (BAP1-TPDS): two invasive melanomas arising in BIMT and two BIMTs with uncertain malignant potential. Molecular analysis and fluorescence in situ hybridization (FISH) revealed <i>BAP1</i> and <i>NRAS</i> mutations in melanoma and BAP1-inactivated melanocytic tumor components, with a gain of 6p25 (<i>RREB1</i>) in the melanoma component only. The patient completed pembrolizumab adjuvant therapy with no evidence of metastasis. This is a rare presentation of BIMT with <i>BAP1</i> and <i>NRAS</i> mutations, absence of <i>BRAF</i> V600 mutation, and loss of BAP1 immunoreactivity in all lesional cells. Our case adds to the understanding of the histomorphologic and mutational spectrum in BAP1-inactivated melanocytic tumors.</p>\n </div>","PeriodicalId":15407,"journal":{"name":"Journal of Cutaneous Pathology","volume":"52 10","pages":"627-635"},"PeriodicalIF":1.1000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Pathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cup.14839","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BAP1-inactivated melanocytic tumor is a distinct entity with loss of BAP1 protein and epithelioid morphology. It shares histopathologic features with Spitz nevus and nevoid melanoma, and it can occur sporadically or with germline BAP1 predisposition syndrome. These lesions typically have tumor-infiltrating lymphocytes and infrequent mitoses. They are generally indolent, though melanoma can arise in both germline and sporadic cases. Most show BRAF V600E and BAP1 mutations. We describe four tumors in one patient diagnosed with BAP1-tumor predisposition syndrome (BAP1-TPDS): two invasive melanomas arising in BIMT and two BIMTs with uncertain malignant potential. Molecular analysis and fluorescence in situ hybridization (FISH) revealed BAP1 and NRAS mutations in melanoma and BAP1-inactivated melanocytic tumor components, with a gain of 6p25 (RREB1) in the melanoma component only. The patient completed pembrolizumab adjuvant therapy with no evidence of metastasis. This is a rare presentation of BIMT with BAP1 and NRAS mutations, absence of BRAF V600 mutation, and loss of BAP1 immunoreactivity in all lesional cells. Our case adds to the understanding of the histomorphologic and mutational spectrum in BAP1-inactivated melanocytic tumors.
期刊介绍:
Journal of Cutaneous Pathology publishes manuscripts broadly relevant to diseases of the skin and mucosae, with the aims of advancing scientific knowledge regarding dermatopathology and enhancing the communication between clinical practitioners and research scientists. Original scientific manuscripts on diagnostic and experimental cutaneous pathology are especially desirable. Timely, pertinent review articles also will be given high priority. Manuscripts based on light, fluorescence, and electron microscopy, histochemistry, immunology, molecular biology, and genetics, as well as allied sciences, are all welcome, provided their principal focus is on cutaneous pathology. Publication time will be kept as short as possible, ensuring that articles will be quickly available to all interested in this speciality.